CD4 and cancer: Together, these data suggest that targeting the PD-1/PD-L1 axis with PIK-93 and anti–PD-L1 antibodies further increases the recruitment of not only CD4+/CD8+ TILs but also M1 macrophages, thus enhancing the antitumor immune response to cancer immunotherapy.